GlassScriptPhysician profile
Robert T Ferraro
NPI 1124118963
$101,007.87
in general payments reported to CMS, 2019-2025
24 companies · $811 in 2025
The $811 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $17K · 2021: $24K · 2022: $39K · 2023: $6,803 · 2024: $671 · 2025: $811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,852 · Food and Beverage: $2,400 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,852.00 |
| Food and Beverage | $2,400.02 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $84,879.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $9,796.04 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $3,152.93 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $977.34 | 2020-2025 | Freestyle Libre 3, Proclaim, Eterna |
| Insulet Corporation | $576.77 | 2019-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $268.05 | 2020-2024 | Gvoke Hypopen |
| Medtronic, INC. | $252.63 | 2021-2025 | Minimed 780g |
| Dexcom, INC. | $204.76 | 2019-2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $188.00 | 2019-2022 | |
| Amgen INC. | $152.67 | 2023-2025 | Tepezza, Evenity, Prolia |
| Medtronic Minimed, INC. | $110.69 | 2019-2020 | |
| Lilly USA, LLC | $97.93 | 2023-2024 | Mounjaro, Jardiance, Humulin |
| Mannkind Corporation | $76.81 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.18 | 2020-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $44.66 | 2022-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $32.99 | 2023-2024 | Isturisa, Signifor Lar |
| Alexion Pharmaceuticals, INC. | $21.30 | 2023 | Strensiq |
| Janssen Pharmaceuticals, INC | $15.98 | 2020 | |
| Corcept Therapeutics | $15.85 | 2020 | |
| Ascendis Pharma Endocrinology INC | $14.70 | 2025 | Yorvipath |
| Tactile Systems Technology INC | $14.49 | 2025 | Nimbl, Flexitouch Plus |
| Horizon Therapeutics Plc | $13.72 | 2023 | Tepezza |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 | |
| Radius Health, INC. | $12.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ferraro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.